Showing results (91-100 of 899) with videos related to
Sort By:
Pageof 90
Journal of Hematology & Oncology|May 14, 2025
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomabNicholas J Short, Hagop Kantarjian, Ken Furudate, et al.Blood Cancer Journal|October 21, 2025
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALLNicholas J Short, Elias Jabbour, Walid Macaron, et al.Expert Opinion on Investigational Drugs|June 4, 2011
A potential role of ruxolitinib in leukemiaKiran Naqvi, Srdan Verstovsek, Hagop Kantarjian, et al.Cancer|February 15, 2011
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.Current Hematologic Malignancy Reports|April 29, 2010
Modern treatment programs for adults with acute lymphoblastic leukemiaFarhad Ravandi, Stefan Faderl, Partow Kebriaei, et al.Journal of Hematology|May 15, 2023
Neutropenic Enterocolitis: An Uncommon, but Fearsome Complication of LeukemiaRodrick Babakhanlou, Farhad Ravandi-Kashani, Dimitrios P KontoyiannisAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?Daniel J DeAngelo, Eytan M Stein, Farhad RavandiCancer|January 28, 2004
New agents in acute myeloid leukemia and other myeloid disordersFarhad Ravandi, Hagop Kantarjian, Francis Giles, et al.Current Opinion in Hematology|December 6, 2017
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitorsRita Assi, Hagop Kantarjian, Farhad Ravandi, et al.Expert Review of Clinical Pharmacology|March 30, 2026
Pharmacokinetics, efficacy, and safety of arsenic formulations in acute promyelocytic leukemia treatmentJennifer Marvin-Peek, Wei-Ying Jen, Farhad RavandiPageof 90